Search Results

• • 55 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Osteoporosis: The connection to urologic health

  Author:Angela M. CheungFrom:Canadian Urological Association Journal (Vol. 8, Issue 7-8Suppl5) Peer-Reviewed

  July-August 20141,233 words Report 2050LAuthor(s): Angela M. Cheung, MD, PhD, FRCPC, CCD Introduction Osteoporotic fractures are common in men, particularly in men undergoing androgen deprivation therapy (ADT) for prostate cancer treatment. As outcomes...

• Androgen deprivation therapy induces vitamin K loss in men with prostate cancer.

  Author:Hisashi MatsushimaFrom:Biology and Medicine (Vol. 9, Issue 4) Peer-Reviewed

  July 1, 20173,057 words Report 1400LAbstract Bone strength is determined by bone mineral density (BMD) and bone quality. Bone fractures are serious adverse events in men receiving androgen deprivation therapy (ADT) for prostate cancer. Although it is...

• Social cognitive outcomes are associated with improvements in mobility performance following lifestyle intervention in prostate cancer patients undergoing androgen deprivation therapy.

  Authors:Zachary L. Chaplow, Alexander R. Lucas, Elizabeth Grainger, Christina Simpson, Ciaran M. Fairman, Victoria R. DeScenza, et al.From:PLoS ONE (Vol. 17, Issue 1) Peer-Reviewed

  Jan. 27, 20223,548 words Report 1740LObjective To compare the effects of an exercise and dietary intervention with those of standard-of-care management upon change in lift and carry performance and mobility-related self-efficacy beliefs and explore...

• A comparative study of the effects of medical versus surgical androgen deprivation therapy on health-related quality of life in patients with metastatic carcinoma prostate

  Authors:Prabhjot Singh, Tapan Agrawal, Siddharth Yadav, Brusabhanu Nayak, Amlesh Seth, and Prem DograFrom:Indian Journal of Cancer (Vol. 55, Issue 2) Peer-Reviewed

  April-June 20182,699 words Report 1540LByline: Prabhjot. Singh, Tapan. Agrawal, Siddharth. Yadav, Brusabhanu. Nayak, Amlesh. Seth, Prem. Dogra INTRODUCTION: Androgen deprivation therapy (ADT) is known to adversely affect the quality of life (QoL). One may...

• Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy

  Author:Alvaro MoralesFrom:Canadian Urological Association Journal (Vol. 11, Issue 6) Peer-Reviewed

  June 20171,075 words Report 2040LThe paper by Shayegan et al in this issue of CUAJ represents an important initial step in establishing recommendations for hormonal monitoring in men with prostate cancer on androgen-deprivation therapy (ADT). As...

• In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

  Authors:Daniel L. Suzman and Emmanuel S. AntonarakisFrom:Oncology (Vol. 28, Issue 10) Peer-Reviewed

  Oct. 20141,187 words Report 1670LPRO Medical or surgical castration (also termed androgen deprivation therapy [ADT]) has been the mainstay of therapy for men with newly diagnosed metastatic prostate cancer. However, with the exception of the potential...

• Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion

  Authors:Yang Yu, Qingyun Zhang, Chengzhong Ma, Xue Yang, Rui Lin, Hongxiang Zhang, et al.From:Stem Cell Research & Therapy (Vol. 9, Issue 1) Peer-Reviewed

  Sept. 26, 20185,530 words Report 1690LBackground Androgen deprivation (AD) as the first-line treatment for advanced prostate cancer (PCa) is insufficient for a long-term effect. Castration resistance remains the greatest obstacle in PCa clinical therapy....

• Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

  Authors:Mohammadali Mohammadzadeh Rezaei, Mohammadhadi Mohammadzadeh Rezaei, Alireza Ghoreifi, and Behzad Feyzzadeh KerighFrom:Canadian Urological Association Journal (Vol. 10, Issue 9-10) Peer-Reviewed

  September-October 20164,473 words Report 1880LIntroduction: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is...

• Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.

  Authors:Jae-Uk Jeong, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Sung-Ja Ahn, Woong-Ki Chung, et al.From:PLoS ONE (Vol. 16, Issue 3) Peer-Reviewed

  Mar. 12, 20215,210 words Report 1500LIntroduction To determine the prognostic significance of long-term adjuvant androgen deprivation therapy (A-ADT) over 1 year in achieving undetectable levels of prostate-specific antigen (PSA) less than 0.001 ng/mL in...

• Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy

  Authors:Shintaro Maru, Hideki Uchino, Takahiro Osawa, Satoshi Chiba, Gaku Mouri, and Ataru SazawaFrom:PLoS ONE (Vol. 13, Issue 5) Peer-Reviewed

  May 24, 20183,939 words Report 1460LPurpose Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with...

• Next-generation therapy for residual prostate cancer

  Authors:Raymond A Clarke and Barry J AllenFrom:Immunotherapy (Vol. 5, Issue 11) Peer-Reviewed

  Nov. 20134,735 words Report 1610LAuthor(s): Raymond A Clarke [*] 1 , Barry J Allen 2 KEYWORDS : [alpha]-therapy; actinium; adjuvant therapy; alpharadin; bismuth; prostate cancer therapy; PSMA; radioimmunotherapy; TAT Prostatectomy and...

• Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.

  Authors:Kent Kanao, Takayuki Takahashi, Yuta Umezawa, Takashi Okabe, Go Kaneko, Suguru Shirotake, et al.From:PLoS ONE (Vol. 17, Issue 10) Peer-Reviewed

  Oct. 20, 20223,326 words Report 1490LBackground The treatment landscape for men with metastatic hormone-naïve prostate cancer (mHNPC) has dramatically changed with the approval of next-generation anti-androgen drugs. We compared the treatment efficacy of...

• CUA-CUOG CRPC guidelines: a useful compendium

  Author:Joseph L. ChinFrom:Canadian Urological Association Journal (Vol. 9, Issue 4) Peer-Reviewed

  Apr. 2015912 words Report 1750LUntil recently, the urologist's active involvement in the care of a patient with advanced prostate cancer is confined to the administration of androgen deprivation therapy (ADT). With the development of castration...

• Management of Metastatic Prostate Cancer in Frail/Elderly Patients

  Author:Elizabeth R. KesslerFrom:Oncology (Vol. 32, Issue 11) Peer-Reviewed

  Nov. 20182,490 words Report 1610LAs the world population ages, we can expect to care for an increasing number of older cancer patients. Prostate cancer is inherently a condition that affects patients of advanced age. In caring for these patients who...

• Letters to the editor

  Authors:Molly Stewart, Hannah Wilson, Paul Abel, and Syed Imran Ali ShahFrom:Urologic Nursing (Vol. 36, Issue 4) Peer-Reviewed

  July-August 20162,258 words Letter to the editor... 1780LTo the editor: In their article, "Skeletal Health Part 1: Overview of Bone Health and Management in the Cancer Setting," Turner et al. (2016) describe the potential risks to skeletal health arising from the use of...

• Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study

  Authors:Jun Won Park, Jae Hyun Lee, Hyon Joung Cho, You-Jung Ha, Eun Ha Kang, Kichul Shin, et al.From:PLoS ONE (Vol. 13, Issue 12) Peer-Reviewed

  Dec. 17, 20185,379 words Report 1530LObjectives Although estrogenic modulation of serum urate levels is well-known, the androgenic effect on urate homeostasis remains controversial. We investigated the effect of androgen deprivation therapy (ADT) on...

• CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model

  Authors:Ruisong Ye, Min Pi, John V. Cox, Satoru K. Nishimoto, and L. Darryl QuarlesFrom:Journal of Experimental & Clinical Cancer Research (Vol. 36, Issue 1) Peer-Reviewed

  June 28, 20176,993 words Report 1600LBackground GPRC6A is implicated in the pathogenesis of prostate cancer, but its role remains uncertain because of a purported tolerant gene variant created by substitution of a K..Y polymorphism in the 3rd...

• What we've learned so far about ADT

  Author:Neil E. FleshnerFrom:Canadian Urological Association Journal (Vol. 8, Issue 7-8Suppl4) Peer-Reviewed

  July-August 2014454 words Report 1380LAuthor(s): Neil E. Fleshner, MPH, MD, FRCSC Although the use of androgen deprivation has been with us for over 60 years, we continue to learn more and more about the androgen axis, how best to suppress it, and how to...

• Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma

  Authors:Chi-Ho Lee, Gang Huang, Pak-Hei Chan, Jojo Hai, Chun-Yip Yeung, Carol Ho-Yi Fong, et al.From:PLoS ONE (Vol. 12, Issue 2) Peer-Reviewed

  Feb. 3, 20174,515 words Report 1790LObjective Androgen deprivation therapy (ADT) increases fracture risk in men with carcinoma of the prostate, but little is known about the fracture risk for different types of ADT. We studied the fracture risk amongst...

• Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-[kappa]B-mediated PTP1B expression

  Authors:I-Chen Yu, Hung-Yun Lin, Ning-Chun Liu, Janet D. Sparks, Shuyuan Yeh, Lei-Ya Fang, et al.From:Diabetes (Vol. 62, Issue 2) Peer-Reviewed

  Feb. 20135,819 words Report 1530LClinical investigations highlight the increased incidence of metabolic syndrome in prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT). Studies using global androgen receptor (AR) knockout mice...